Quantitative EEG and apolipoprotein E-genotype improve classification of patients with suspected Alzheimer's disease

Clinical Neurophysiology

Volumn 124, Issue 11, 2013, Pages 2146-2152

  Hatz, F ^a   Benz, N ^a   Hardmeier, M ^a   Zimmermann, R ^a   Rueegg, S ^a   Schindler, C ^a   Miserez, A R ^b   Gschwandtner, U ^a   Monsch, A U ^a   Fuhr, P ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Diagene Inc   (Switzerland)

Author keywords

Alzheimer's disease; Electroencephalography; Frequency analysis; LORETA; Mild cognitive impairment; Surrogate marker; Topographic analysis

Indexed keywords

APOLIPOPROTEIN E;

ALZHEIMER DISEASE; AMNESIA; ARTICLE; BODY MOVEMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; EDUCATIONAL STATUS; ELECTROENCEPHALOGRAPHY; EPISODIC MEMORY; EXECUTIVE FUNCTION; GENDER; GENE FREQUENCY; GENOTYPE; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; VERBAL MEMORY;

EID: 84885857215     PISSN: 13882457     EISSN: 18728952     Source Type: Journal    
DOI: 10.1016/j.clinph.2013.04.339     Document Type: Article

References (48)

1. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer Dement 2011, 7:270-279.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th ed. 1994, American Psychiatric Association, Washington, DC.
3. Arlt S., Brassen S., Jahn H., Wilke F., Eichenlaub M., Apostolova I., et al. Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009, 36:1090-1100.
4. Army Individual Test Battery. Manual of Directions and scoring. Washington, DC: War Department, Adjutant General's, Office, 1944.
5. Aubert-Broche B., Evans A.C., Collins L. A new improved version of the realistic digital brain phantom. Neuroimage 2006, 32:138-145.
6. Babiloni C., Cassetta E., Binetti G., Tombini M., Del Percio C., Ferreri F., et al. Resting EEG sources correlate with attentional span in mild cognitive impairment and Alzheimer's disease. Eur J Neurosci 2007, 25:3742-3757.
7. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031.
8. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
9. Beck I., Gagneux A., Berres M., Monsch A. Comparison of verbal episodic memory measures: consortium to establish a registry for Alzheimer's disease-neuropsychological assessment battery (CERD-NAB) vs. California verbal learning test (CVLT). Arch Clin Neuropsychol 2012, 27:510-519.
10. Berres M., Monsch A.U., Bernasconi F., Thalmann B., Stahelin H.B. Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease. Stud Health Technol Inform 2000, 77:195-199.
11. Bové J., Martínez-Vicente M., Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 2011, 12:437-452.
12. Brunet D., Murray M.M., Michel C.M. Spatiotemporal analysis of multichannel EEG: CARTOOL. Comput Intell Neurosci 2011, 2011:813870.
13. De Haan W., Mott K., vanStraaten E.C.W., Scheltens P., Stam C.J. Activity dependent degeneration explains hub vulnerability in Alzheimer's disease. PLoS Comput Biol 2012, 8:e1002582.
14. Delis D., Kramer J., Ober B., Kaplan E. The California verbal learning test: administration and interpretation 1987, Psychological Corporation, San Antonio, TX.
15. Delorme A., Makeig S. EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods 2004, 134:9-21.
16. Duara R., Loewenstein D.A., Greig M.T., Potter E., Barker W., Raj A., et al. Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. Am J Geriatr Psychiatry 2011, 19:951-960.
17. Elias-Sonnenschein L.S., Viechtbauer W., Ramakers I.H.G.B., Verhey F.R.J., Visser P.J. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis. J Neurol Neurosurg Psychiatry 2011, 82:1149-1156.
18. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
19. Frei E., Gamma A., Pascual-Marqui R., Lehmann D., Hell D., Vollenweider F.X. Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA). Hum Brain Mapp 2001, 14:152-165.
20. Frisoni G.B., Fox N.C., Jack C.R., Scheltens P., Thompson P.M. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010, 6:67-77.
21. Gasser T., Bächer P., Möcks J. Transformations towards the normal distribution of broad band spectral parameters of the EEG. Electroencephalogr Clin Neurophysiol 1982, 53:119-124.
22. Halper A., Cherney L. Cognitive-communication problems after right hemisphere stroke: a review of intervention studies. Top Stroke Rehabil 1985, 55:1-10.
23. Härtig C., Markowitsch H.J., Neufeld H., Calabrese P., Deisinger K., Kessler J. Wechsler Gedächtnis Test - Revisierte Fassung 2000, Verlag Hans Huber, Bern.
24. Herholz K., Carter S.F., Jones M. Positron emission tomography imaging in dementia. Br J Radiol 2007, 80:160-167.
25. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990, 31:545-548.
26. Isaacs B., Kennie A.T. The set test as an aid to the detection of dementia in old people. Br J Psychiatry 1973, 123:467-470.
27. Jagust W., Gitcho A., Sun F., Kuczynski B., Mungas D., Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol 2006, 59:673-681.
28. Jelic V., Julin P., Shigeta M., Nordberg A., Lannfelt L., Winblad B., Wahlund L.O. Apolipoprotein E ε4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence. J Neurol Neurosurg Psychiatry 1997, 63:59-65.
29. Lehtovirta M., Partanen J., Könönen M., Hiltunen J., Helisalmi S., Hartikainen P., Riekkinen P., Soininen H.A. Longitudinal quantitative EEG study of Alzheimer's disease: relation to apolipoprotein E polymorphism. Dement Geriatr Cogn Disord 2000, 11:29-35.
30. Maris E., Oostenveld R. Nonparametric statistical testing of EEG- and MEG-data. J Neurosci Methods 2007, 64:177-190.
31. McKhann G., Drachman D., Folstein M.F., Price, Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
32. Miserez A.R., Laager R., Chiodetti N., Keller U. High prevalence of familial defective apolipoprotein B-100 in Switzerland. J Lipid Res 1994, 35:574-583.
33. Monsch A.U., Kressig R.W. Specific care program for the older adults: memory clinics. Eur Geriatr Med 2010, 1:128-131.
34. Morris J.C., Heyman A., Mohs R.C., Hughes J.P., van Belle G., Fillenbaum G., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989, 39:1159-1165.
35. Nolan H., Whelan R., Reilly R.B. FASTER: fully automated statistical thresholding for EEG artifact rejection. J Neurosci Methods 2010, 192:152-162.
36. Osterrieth P.A. Le test de copie d'une figure complexe; contribution à l'étude de la perception et de la mémoire. [Test of copying a complex figure; contribution to the study of perception and memory.]. Arch Psychol (Geneve) 1944, 30:206-356.
37. Ponomareva N.V., Korovaitseva G.I., Rogaev E.I. EEG alterations in non-demented individuals related to apolipoprotein E genotype and to risk of Alzheimer disease. Neurobiol Aging 2008, 29:819-827.
38. Regard M., Strauss E., Knapp P. Children's production on verbal and non-verbal fluency tasks. Percept Mot Skills 1982, 55:839-844.
39. Roh J.H., Park M.H., Ko D., Park K.W., Lee D.H., Han C., et al. Region and frequency specific changes of spectral power in Alzheimer's disease and mild cognitive impairment. Clin Neurophys 2011, 122:2169-2176.
40. Sheikh J.A., Yesavage J.A. Geriatric depression scale (gds): recent findings and development of a shorter version. Clinical gerontology: a guide to assessment and intervention 1986, Haworth Press, New York, 165-173.
41. Spreen O., Strauss E. A compendium of neuropsychological tests 1998, Oxford University Press, New York. 2nd ed.
42. Thurstone L.L., Thurstone T.M. The chicago test of primary mental abilities 1948, Science Research Associates, Chicago.
43. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM Using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15:273-289.
44. van der Hiele K., Vein A.A., Reijntjes R.H.A.M., Westendorp R.G.J., Bollen E.L.E.M., van Buchem M.A., et al. EEG correlates in the spectrum of cognitive decline. Clin Neurophys 2007, 118:1931-1939.
45. Wagner S.L., Tanzi R.E., Mobley W.C., Galasko D. Potential use of γ-secretase modulators in the treatment of Alzheimer disease. Arch Neurol 2012, 69:1255-1258.
46. Welch P. The use of fast Fourier transform for the estimation of power spectra: a method based on time averaging over short, modified periodograms. IEEE Trans Acous 1967, 15:70-73.
47. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., et al. Mild cognitive impairment; beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004, 256:240-246.
48. Zimmermann P., Fimm B. Psytest Psychologische Testsysteme 2007, Herzogenrath, Germany.